Nagai Aiko, Shibamoto Yuta, Yoshida Masanori, Inoda Koji, Kikuchi Yuzo
Radiation Therapy Center, Fukui Saiseikai Hospital, 7-1, Funabashi, Wadanaka-cho, Fukui 918-8503, Japan.
Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
J Radiat Res. 2017 Jul 1;58(4):529-536. doi: 10.1093/jrr/rrw132.
This study investigated the differences in dose-volume parameters for the breast and normal tissues during TomoDirectTM (TD) intensity-modulated radiation therapy (IMRT), TD-3D conformal radiotherapy (3DCRT) and 3DCRT plans, all using two beams, and analyzed treatment outcomes of two-beam TD-IMRT for breast cancer after breast-conserving surgery. Between August 2011 and January 2015, 152 patients were treated using two-beam TD-IMRT with 50 Gy/25 fractions. Among them, 20 patients with left-sided breast cancer were randomly chosen, and two-beam TD-IMRT, TD-3DCRT and 3DCRT plans were created for each patient. The homogeneity and conformity indices and various dose-volume parameters for the planning target volume and OARs were evaluated. Clinical outcomes were evaluated at 3 years. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. TD-IMRT and TD-3DCRT showed better whole-breast coverage than 3DCRT (P < 0.001). Most of the mean values of dosimetric endpoints for OARs were better in TD-IMRT than in TD-3DCRT and 3DCRT. Overall survival rates were 97.7% and local control rates were 99.1% at 3 years. Regional control and distant metastasis control rates at 3 years were 98.6% and 96.8%, respectively. Twenty-four of the 152 patients had Grade 2 or higher acute radiation dermatitis. Four patients (4/146 = 2.7%) had Grade 2 radiation pneumonitis. There were no late adverse events of Grade 2 or higher. Two-beam TD-IMRT appeared to yield better dose distribution for whole-breast external-beam radiation therapy than TD-3DCRT and two-beam 3DCRT. The treatment appeared to provide low skin toxicity and acceptable tumor control.
本研究调查了TomoDirectTM(TD)调强放射治疗(IMRT)、TD三维适形放射治疗(3DCRT)和3DCRT计划(均采用两野照射)期间乳腺及正常组织的剂量体积参数差异,并分析了保乳手术后乳腺癌两野TD-IMRT的治疗结果。2011年8月至2015年1月期间,152例患者接受了50 Gy/25次分割的两野TD-IMRT治疗。其中,随机选取20例左侧乳腺癌患者,为每位患者制定两野TD-IMRT、TD-3DCRT和3DCRT计划。评估了计划靶区和危及器官的均匀性和适形性指数以及各种剂量体积参数。在3年时评估临床结果。使用不良事件通用术语标准第4.0版评估毒性。TD-IMRT和TD-3DCRT的全乳覆盖情况优于3DCRT(P < 0.001)。TD-IMRT中大多数危及器官剂量学终点的平均值优于TD-3DCRT和3DCRT。3年时总生存率为97.7%,局部控制率为99.1%。3年时区域控制率和远处转移控制率分别为98.6%和96.8%。152例患者中有24例发生2级或更高等级的急性放射性皮炎。4例患者(4/146 = 2.7%)发生2级放射性肺炎。未发生2级或更高等级的晚期不良事件。两野TD-IMRT在全乳外照射放疗中似乎能产生比TD-3DCRT和两野3DCRT更好的剂量分布。该治疗似乎具有低皮肤毒性和可接受的肿瘤控制效果。